ClinicaliQ Trial Snapshot
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Recruiting • Phase III • Gastroenterology • NCT06528314.
- What is being tested: Efruxifermin (EFX), an FGF21 analogue, is being evaluated in a randomized controlled trial to assess its efficacy and safety in treating compensated cirrhosis secondary to NASH/MASH (metabolic dysfunction-associated fatty liver disease).
- Patient eligibility overview: The study enrolls patients with biopsy-confirmed or imaging/biomarker-diagnosed compensated cirrhosis specifically attributable to NASH/MASH, excluding those with decompensated liver disease or alternative aetiologies of cirrhosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Eligibility Snapshot
- : * Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH and NAS score of >=3 (at least 1 in each category) or evidence of steatosis and 2 current features of metabolic comorbidities * Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.